Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Trial Profile

Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Methylprednisolone (Primary) ; Ublituximab (Primary)
  • Indications Neuromyelitis optica; Optic neuritis
  • Focus Adverse reactions; Proof of concept
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 20 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 20 Dec 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017.
    • 20 Dec 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top